New hope for patients with Hard-to-Control blood disorder
NCT ID NCT06477653
Summary
This study is testing whether adding an approved drug called dupilumab helps people with hypereosinophilic syndrome (HES) who still have symptoms like breathing problems or skin issues despite taking other biologic medications. The goal is to see if the combination better controls their disease and improves daily life. About 30 adults who are already on specific HES treatments will receive dupilumab injections at home for up to 48 weeks while doctors monitor their symptoms and blood counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.